The article frames this as the provider weighing metabolic benefits against inflammatory bowel disease risk on an individual basis rather than applying a general rule
Week one through two: Use GHK-CU once every third day at the lowest available concentration or dose
[22] [3] However, some patients report variations in appetite suppression during the week following injection
Its balanced formula combines glutathione, PDRN, and a peptide complex to help the skin look smoother, fresher, and more radiant without a heavy feel
WADA Prohibition Status Based on WADAs prohibition categories: GLP3 likely falls under Section S0 (Non-Approved Substances) of the WADA Prohibited List, which includes: Any pharmacological substance not approved by governmental regulatory health authorities for human therapeutic use Drugs under preclinical or clinical development Substances without current regulatory approval from any health authority worldwide Implications for competitive athletes: Prohibited at all times (in-competition and out-of-competition) No Therapeutic Use Exemptions available for unapproved substances Use could result in anti-doping rule violations and sanctions Detection methods under development as clinical trials progress Research Classification: GLP3 is available exclusively for use in FDA-approved clinical trials under Investigational New Drug applications
But they do not directly treat every type of GLP-1 nausea